Incidence of cutaneous adverse events after exposure to tenofovir–emtricitabine in HIV-uninfected vs HIV-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program

C. Kosche, A. Para, J. Brieva, D. P. West, F. J. Palella, B. Nardone*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)e470-e471
JournalJournal of the European Academy of Dermatology and Venereology
Volume33
Issue number12
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this